Sandeep Singh Sidhu, Barjesh Chander Sharma, Omesh Goyal, Harsh Kishore, Navpreet Kaur – 27 July 2017 – High‐quality data on the efficacy of L‐ornithine L‐aspartate (LOLA) in patients with cirrhosis and bouts of overt hepatic encephalopathy (OHE) are missing. We evaluated the efficacy of intravenous LOLA in the reversal of bouts of OHE in patients with cirrhosis. In this prospective, double‐blind, randomized, placebo‐controlled trial conducted at two tertiary care institutes in India, 370 patients with cirrhosis and bouts of OHE were screened.

Masashi Hirooka, Yohei Koizumi, Teruki Miyake, Takao Watanabe, Osamu Yoshida, Yoshio Tokumoto, Atsushi Yukimoto, Yoshiko Nakamura, Yusuke Imai, Masanori Abe, Yoichi Hiasa – 27 July 2017 – A change in hepatic blood flow caused by the hepatic arterial buffer response (HABR) occurs as fatty liver disease progress. The aim of this longitudinal cohort study was to investigate whether fatty liver with the HABR induces metabolic disorders. In 2009 and 2010, 494 (89.5%) participants were enrolled. The median follow‐up duration was 5.0 (interquartile range, 3.9‐6.0) years.

Gaiyun Li, Yuanfei Zhu, Dianhui Shao, Hao Chang, Xiaoming Zhang, Dongming Zhou, Yueqiu Gao, Ke Lan, Qiang Deng – 27 July 2017 – Covalently closed circular DNA of hepatitis B virus (HBV) is critical for viral persistence in vivo. We recently reported a technique involving recombinant covalently closed circular DNA (rcccDNA) of HBV by site‐specific DNA recombination. Using hydrodynamic injection, rcccDNA induces a temporarily prolonged HBV antigenemia in immunocompetent mice, similar to acute resolving HBV infection.

Michael M.C. Lai, Wen‐Chi Su – 27 July 2017

Diego Moya‐Nájera, Ángel Moya‐Herraiz, Luis Compte‐Torrero, David Hervás, Sebastien Borreani, Joaquin Calatayud, Marina Berenguer, Juan C. Colado – 27 July 2017 – Although currently moderate and high intensity concurrent physical exercise is prescribed in populations with special needs due to its greater effect on physical condition and health‐related quality of life (HRQOL), there are no data in the liver transplantation (LT) setting.

Sandeep Singh Sidhu, Barjesh Chander Sharma, Omesh Goyal, Harsh Kishore, Navpreet Kaur – 27 July 2017 – High‐quality data on the efficacy of L‐ornithine L‐aspartate (LOLA) in patients with cirrhosis and bouts of overt hepatic encephalopathy (OHE) are missing. We evaluated the efficacy of intravenous LOLA in the reversal of bouts of OHE in patients with cirrhosis. In this prospective, double‐blind, randomized, placebo‐controlled trial conducted at two tertiary care institutes in India, 370 patients with cirrhosis and bouts of OHE were screened.

Jiwei Zhang, Zhe Li, Longzi Liu, Qifeng Wang, Shengli Li, Di Chen, Zhixiang Hu, Tao Yu, Jie Ding, Jinjun Li, Ming Yao, Shenglin Huang, Yingjun Zhao, Xianghuo He – 26 July 2017 – Long noncoding RNAs can serve as oncogenes or tumor suppressors in human cancer; however, their biological functions and underlying mechanism in hepatocarcinogenesis are largely unknown. Here, we report a novel tumor suppressor long noncoding RNA on chromosome 8p12 (termed TSLNC8) that is frequently deleted and down‐regulated in hepatocellular carcinoma (HCC) tissues.

Jin‐Kyu Park, Yasuko Iwakiri – 26 July 2017

Koichi Fujisawa, Taro Takami, Toshihiko Matsumoto, Naoki Yamamoto, Isao Sakaida – 26 July 2017 – Liver cirrhosis can disturb circadian rhythms, decreasing patient quality of life. Changes in metabolic products in cirrhosis are poorly understood. We evaluated changes in liver metabolism products using a thioacetamide‐induced mouse model of liver cirrhosis exhibiting circadian rhythm disturbance.

Shikun Yang, Jianhua Rao – 26 July 2017